key: cord-0962578-ubnvvvj0 authors: Parohan, M.; Yaghoubi, S.; Djalali, M.; Seraji, A.; Javanbakht, M. H.; Mousavi, Z. title: Acute kidney injury is associated with severe and fatal outcomes in patients with Coronavirus disease 2019 (COVID-19) infection: a systematic review and meta-analysis of observational studies date: 2020-09-01 journal: nan DOI: 10.1101/2020.08.27.20183632 sha: 61f979842f60694d52e36f1a6547f892c10c89e7 doc_id: 962578 cord_uid: ubnvvvj0 Coronavirus disease 2019 (COVID-19) is a pandemic impacting 213 countries and territories with more than 17,918,582 cases worldwide. Kidney dysfunction has been reported to occur in severe and death cases. This meta-analysis was done to summarize available studies on the association between acute kidney injury and severity of COVID-19 infection. Online databases including Web of Science, PubMed/Medline, Cochrane Library, Scopus and Google Scholar were searched to detect relevant articles up to 1 July 2020, using relevant keywords. To pool data, a random- or fixed-effects model was used based on the heterogeneity between studies. In total, 50 studies with 8,180 COVID-19 confirmed cases (severe cases=1,823 and death cases=775), were included in this meta-analysis. Higher serum levels of creatinine (weighted mean difference (WMD) for disease severity=5.47 mol/L, 95% CI=2.89 to 8.05, P<0.001 and WMD for mortality=18.32 mol/L, 95% CI=12.88 to 23.75, P<0.001), blood urea nitrogen (BUN) (WMD for disease severity=1.10 mmol/L, 95% CI=0.67 to 1.54, P<0.001 and WMD for mortality=3.56 mmol/L, 95% CI=2.65 to 4.48, P<0.001) and lower levels of estimated glomerular filtration rate (eGFR) (WMD for disease severity=-15.34 mL/min/1.73 m2, 95% CI=-18.46 to -12.22, P<0.001 and WMD for mortality=-22.74 mL/min/1.73 m2, 95% CI=-27.18 to -18.31, P<0.001) were associated with a significant increase in the severity and mortality of COVID-19 infection. Acute kidney injury, as assessed by kidney biomarkers (serum creatinine, BUN and eGFR), was associated with severe outcome and death from COVID-19 infection. Coronavirus disease 2019 (COVID-19) is a global pandemic impacting 213 countries, areas and territories with a total of 17,918,582 confirmed cases and 686,703 deaths worldwide 1 . As the COVID-19 outbreak expands, identification of clinical and laboratory predictors for severe and fatal outcomes are essential to enable risk stratification, guide public health recommendations and optimize allocation of limited hospital resources in the ongoing pandemic. Genome sequencing showed that the COVID-19 belongs to β genus of Coronavirus, which also includes Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS) 2 . Similar to SARS, COVID-19 infection is caused by binding of the virus to the angiotensin-converting enzyme 2 (ACE2) receptors 3 . ACE2 receptors are highly expressed in the lungs, kidneys, heart, vascular endothelium, liver and intestinal epithelium, providing a mechanism for the multi-organ dysfunction that can be seen with COVID-19 infection 4, 5 . Multiple observational studies have reported the clinical features and laboratory findings associated with acute kidney injury in patients with COVID-19 infection . In this study, the laboratory findings and mechanism of kidney dysfunction caused by COVID-19 were summarized. A systematic literature search was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 56 . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, . . https://doi.org/10.1101 Discussion Findings from this meta-analysis showed that kidney dysfunction is associated with severe outcome and death from COVID-19 infection. To our best knowledge, this study is the first meta-analysis to assess the association between kidney biomarkers, in particular eGFR and severity of COVID-19 infection. The findings from our study are in agreement with previous reviews [61] [62] [63] [64] . Previously, kidney injury has been reported as a significant risk factor for severe outcome and death in SARS and MERS 65, 66 . COVID-19 may either exacerbate preexisting chronic kidney diseases and/or induce new acute kidney injuries. Earlier studies have shown that the incidence of acute kidney injury in severe COVID-19 patients and death cases ranged from 3.7% to 70.7% and 18.3% to 73.7%, respectively 10, 25, 37, 45 . The pathophysiology of COVID-19 associated acute kidney injury could be related to specific and nonspecific mechanisms. Specific mechanisms include direct cellular injury resulting from viral entry through the angiotensin-converting enzyme 2 receptor which is highly expressed in the kidneys 3, 67 , an imbalanced renin-angiotensin-aldosterone system activation, leading to vasoconstriction, inflammation and fibrosis 68, 69 , cytokine storm, mediated by increased proinflammatory cytokine production after COVID-19 infection 61 and thrombotic events 70 . Nonspecific mechanisms include hypovolemia 8 , right heart failure, hemodynamic changes such as central venous pressure elevation and increased intra-thoracic pressure 71 , high levels of positive end-expiratory pressure in patients requiring mechanical ventilation 72, 73 , nosocomial . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, . . https://doi.org/10.1101 sepsis and administration of nephrotoxic drugs, especially antibiotics, antiviral therapy and/or traditional medicine 61 . Furthermore, increased fraction of inspired oxygen (FiO2) requirement and respiratory failure can also contribute to renal hypoperfusion and medullary hypoxia resulting from combined effects of third-space fluid loss, endothelial damage and hypotension from COVID-19-induced cytokine release 74 . Urine sediments of COVID-19 infected patients showed subnephrotic microhematuria and proteinuria, which are consistent with autopsy findings of kidney tissues of these patients showing proximal tubule injury with erythrocyte aggregates obstructing the peritubular capillaries and tubular necrosis with macrophage infiltration 70 . Until effective therapies against COVID-19 become available, the treatment of disease will be primarily based on the treatment of complications. Treatment of kidney complications should be based on optimal use of guideline-based therapies. This study has some limitations. First, interpretation of results might be limited by the low sample size. Second, the present study did not include data such as smoking history and body mass index and, which are potential risk factors for disease severity. In this meta-analysis of 8,180 COVID-19 infected patients, acute kidney injury as assessed by serum levels of creatinine, BUN and eGFR was associated with severe outcome and death from COVID-19 infection. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . The authors report no conflict of interest. None. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . H e a l t h O r g a n i z a t i o n . C o r o n a v i r u s d i s e a s e 2 0 1 9 ( C O V I D -1 9 ) : s i t u a t i o n r e p o r t -1 9 6 . A u g u s t 3 , 2 0 2 0 . 2 . Z h u N , Z h a n g D , W a n g W , L i X , Y a n g B , S o n g J , e t a l . A N o v e l C o r o n a v i r u s f r o m P a t i e n t s w i t h P n e u m o n i a i n C h i n a , 2 0 1 9 . N E n g l J M e d . 2 0 2 0 ; 3 8 2 ( 8 ) : 7 2 7 -3 3 . 3 . H o f f m a n n M , K l e i n e -W e b e r H , S c h r o e d e r S , K r ü g e r N , H e r r l e r T , E r i c h s e n S , e t a l . . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . a l o u t c o m e a n d d i f f e r e n c e s i n p o s t -t r e a t m e n t h o s p i t a l i s a t i o n s t a t u s . P h a r m a c o l R e s . 2 0 2 0 ; 1 5 8 : 1 0 4 8 9 9 . 2 2 . C a o Z , L i T , L i a n g L , W a n g H , W e i F , M e n g S , e t a l . C l i n i c a l c h a r a c t e r i s t i c s o f C o r o n a v i r u s D i s e a s e 2 0 1 9 p a t i e n t s i n B e i j i n g , C h i n a . P L o S O n e . 2 0 2 0 ; 1 5 ( 6 ) : e 0 2 3 4 7 6 4 . 2 3 . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . C h e n Y T , S h a o S C , H s u C K , W u I W , H u n g M J , C h e n Y C . I n c i d e n c e o f a c u t e k i d n e y i n j u r y i n C O V I D -1 9 i n f e c t i o n : a s y s t e m a t i c r e v i e w a n d m e t a -a n a l y s i s . C r i t C a r e . 2 0 2 0 ; 2 4 ( 1 ) : 3 4 6 . 6 3 . A l i H , D a o u d A , M o h a m e d M M , S a l i m S A , Y e s s a y a n L , B a h a r a n i J , e t a l . S u r v i v a l r a t e i n a c u t e k i d n e y i n j u r y s u p e r i m p o s e d C O V I D -1 9 p a t i e n t s : a s y s t e m a t i c r e v i e w a n d m e t a -a n a . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted September 1, 2020. . Retrospective China 57 161 Severe cases: 30 Mild cases NOTE: Weights are from random effects analysis . Overall (I-squared = 64 Subtotal (I-squared = 64.5%, p = 0.000) 2020 (a) 2020 (a) 2020 (a) Overall (I-squared = 88.4%, p = 0.000) ID 2020 (a) 2020 (b) Non-survivor vs survivor Subtotal (I-squared = 72.4%, p = 0.001) 2020 (a) 2020 (b) Subtotal (I-squared = 77.3%, p = 0.000) 2020 (a) Heterogeneity between groups: p = 0 Overall (I-squared = 38 Subtotal (I-squared = 0.0% Subtotal (I-squared = 43 Non-survivor vs survivor NOTE: Weights are from random effects analysis Overall (I-squared = 64 2020 (b) 2020 (b) 2020 (b)